Raniclor Side Effects
Generic Name: cefaclor
Note: This page contains side effects data for the generic drug cefaclor. It is possible that some of the dosage forms included below may not apply to the brand name Raniclor.
It is possible that some side effects of Raniclor may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to cefaclor: oral capsules, oral extended-release tablets, oral for suspension
Side effects include:
Diarrhea, genital pruritus or vaginitis, headache, nausea, vomiting, rash.
For Healthcare Professionals
Applies to cefaclor: oral capsule, oral powder for reconstitution, oral tablet chewable, oral tablet extended release
If diarrhea occurs and it is unresponsive to discontinuation of the drug and/or standard therapy, pseudomembranous colitis should be considered.[Ref]
Gastrointestinal side effects have included diarrhea, nausea, vomiting, and abdominal pain. Extended-release cefaclor has been associated with diarrhea (3.8%), nausea (3.4%), and anorexia, constipation, dyspepsia, flatulence, gastritis, nausea and vomiting, and vomiting in 0.1% to 1% of patients. Pseudomembranous colitis has been reported in patients treated with cephalosporins.[Ref]
Anaphylactic reactions are rare, but may occur, especially in patients with a history of penicillin allergy.
Serum-sickness-like reactions are more frequent in pediatric patients and following a second or subsequent course of cefaclor (the active ingredient contained in Raniclor) and have been characterized by erythema multiforme, rash, arthritis, and/or arthralgia with or without fever.[Ref]
Hypersensitivity reactions have included rash, morbilliform eruptions (1%), pruritus, serum-sickness-like reactions, urticaria, anaphylactic reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylactoid reaction, and angioedema.[Ref]
Hepatic side effects have included slight elevations AST, ALT, and alkaline phosphatase in 2.5% of patients. Extended-release cefaclor (the active ingredient contained in Raniclor) has been associated with increased ALT (0.3%), increased alkaline phosphatase (0.3%), increased bilirubin (0.3%), increased creatine phosphokinase (0.7%), and increased GGT (0.2%). Cephalosporins as a class have been associated with elevated LDH, hepatic dysfunction, and cholestasis.[Ref]
One case report of acute interstitial nephritis and nonoliguric renal failure has been reported following cefaclor (the active ingredient contained in Raniclor) therapy. (Reversible fever, azotemia, pyuria, and eosinophiluria are the hallmarks of cephalosporin-induced interstitial nephritis.)[Ref]
Renal side effects have included transient elevations in blood urea nitrogen (BUN) and serum creatinine in 0.2% of patients, reversible interstitial nephritis (rare), and abnormal urinalysis (0.5%). Extended-release cefaclor has been associated with increased BUN (0.2%), and increased creatinine (0.5%). Cephalosporins as a class have been associated with toxic nephropathy, reversible interstitial nephritis, and renal dysfunction.[Ref]
Hematologic side effects have included eosinophilia (2%), positive Coombs' test (less than 0.5%), leukopenia, thrombocytosis, transient thrombocytopenia (rare), transient lymphocytosis, hemolytic anemia, aplastic anemia, agranulocytosis, and reversible neutropenia. Extended-release cefaclor (the active ingredient contained in Raniclor) has been associated with increased eosinophils (0.3%), decreased erythrocyte count (0.3%), decreased hemoglobin (0.2%), decreased lymphocytes (0.3%), increased mean cell volume (0.7%), decreased segmented neutrophils (0.3%), and decreased platelet count (0.4%). Cephalosporins as a class have been associated with hemorrhage and pancytopenia.[Ref]
Genitourinary side effects have included genital pruritus and vaginitis in less than 1% of patients. Extended-release cefaclor (the active ingredient contained in Raniclor) has been associated with vaginitis (2.4%) and vaginal moniliasis (2.2%), and dysmenorrhea, dysuria, leukorrhea, menstrual disorder, and nocturia in 0.1% to 1% of patients. Cephalosporins as a class have been associated with false-positive tests for urine glucose.[Ref]
Nervous system side effects have rarely included reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, and somnolence. Extended release cefaclor (the active ingredient contained in Raniclor) has been associated with headache in 4.9% of patients, and dizziness, insomnia, nervousness, somnolence, and tremor in 0.1% to 1% of patients, and paresthesia and vertigo. Some cephalosporins have been associated with seizures, primarily when dosages were not reduced in renally impaired patients.[Ref]
Other side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included abdominal pain (1.6%), back pain (1%), and accidental injury, chest pain, chills, ear pain, fever, flu syndrome, infection, malaise, neck pain, otitis media, pain, and surgical procedure in 0.1% to 1% of patients. Cephalosporins as a class have been associated with abdominal pain, fever, and superinfection.[Ref]
Respiratory side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included rhinitis (3.9%), increased cough (1.5%), pharyngitis (1.4%), and asthma, bronchitis, lung disorder, respiratory disorder, and sinusitis in 0.1% to 1% of patients.[Ref]
Dermatologic side effects have included pruritus, maculopapular rash, rash, and urticaria.[Ref]
Musculoskeletal side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included arthralgia and myalgia in 0.1% to 1% of patients.[Ref]
Cardiovascular side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included congestive heart failure (0.1% to 1%), edema (0.1% to 1%), palpitation (0.1% to 1%), peripheral edema (0.1% to 1%), hypotension, face edema, vasodilatation, and syncope.[Ref]
Ocular side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included conjunctivitis (0.1% to 1%).[Ref]
Endocrine side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included sweating (0.1% to 1%).[Ref]
Metabolic side effects associated with extended-release cefaclor (the active ingredient contained in Raniclor) have included decreased albumin (0.3%), decreased calcium (0.7%), increased creatine phosphokinase (0.7%), increased phosphorus (0.7%), increased potassium (0.4%), decreased sodium (0.3%), and increased sodium (0.4%).[Ref]
1. Quenzer RW, Davis RL, Neidhart MM "Prospective randomized study comparing the efficacy and safety of ciprofloxacin with cefaclor in the treatment of patients with purulent bronchitis." Diagn Microbiol Infect Dis 13 (1990): 143-8
2. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals, San Diego, CA.
3. Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988): 83-94
4. Goumas P, Naxakis S, Bassaris C, Skoutelis A "Comparative efficacy and tolerability of clarithromycin and cefaclor in the treatment of outpatients with acute maxillary sinusitis." Clin Drug Invest 13 (1997): 128-33
5. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company, Indianapolis, IN.
6. Reynolds RD "Cefaclor and serum sickness-like reaction." JAMA 276 (1996): 950
7. Beghetti M, Wilson GJ, Bohn D, Benson L "Hypersensitivity myocarditis caused by an allergic reaction to cefaclor." J Pediatr 132 (1998): 172-3
8. Boyd LW "Cefaclor-associated serum sickness." Med J Aust 169 (1998): 443-4
9. Ackley AM, Felsher J "Adverse reactions to cefaclor." South Med J 74 (1981): 1550
10. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226
11. Hama R, Mori K "High incidence of anaphylactic reactions to cefaclor." Lancet 06/11/88 (1988): 1331
12. Grouhi M, Hummel D, Roifman CM "Anaphylactic reaction to oral cefaclor in a child." Pediatrics 103 (1999): e50
13. Christensen JC, Swenson E, Gooch WM, Herrod JN "Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis." Antimicrob Agents Chemother 35 (1991): 1127-30
14. Pommer W, Krause PH, Berg PA, et al "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986): 290-3
15. "Multum Information Services, Inc. Expert Review Panel"
More about Raniclor (cefaclor)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.